Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LAD106 in Healthy Adult Participants
Sponsor: Almirall, S.A.
Summary
The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.
Official title: A Phase 1, Randomized, Two-part, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of LAD106 in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
93
Start Date
2026-02-17
Completion Date
2026-06-30
Last Updated
2026-03-13
Healthy Volunteers
Yes
Conditions
Interventions
LAD106
LAD106 will be administered.
Lebrikizumab
Lebrikizumab will be administered.
Placebo
Placebo matching LAD106 will be administered.
Locations (1)
Centre for Human Drug Research (CHDR) Phase 1 Unit
Leiden, Netherlands